News | January 22, 2024
Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
AMI to become part of Enpro’s Sealing Technologies Segment
Subscribe To Our Newsletter & Stay Updated
